Comparison of newly developed immuno-MS method with existing DELFIA® immunoassay for human chorionic gonadotropin determination in doping analysis

Bioanalysis

Volumn 5, Issue 5, 2013, Pages 623-630

  Lund, Hanne ^a   Snilsberg, Ann Helene ^a   Halvorsen, Trine Grønhaug ^a   Hemmersbach, Peter ^a,b   Reubsaet, Léon ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; HETERODIMER; ILLICIT DRUG;

ANTIBODY AFFINITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOPING; GONADOTROPIN BLOOD LEVEL; HORMONE DETERMINATION; HORMONE URINE LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STORAGE; URINALYSIS;

CHORIONIC GONADOTROPIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMERIZATION; DOPING IN SPORTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOASSAY; TANDEM MASS SPECTROMETRY;

EID: 84874162031     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.8     Document Type: Article

References (24)

1. Stenman UH, Hotakainen K, Alfthan H. Gonadotropins in doping: Pharmacological basis and detection of illicit use. Br. J. Pharmacol. 154(3), 569-583 (2008). (Pubitemid 351744939)
2. Lund H, Løvsletten K, Paus E, Halvorsen TG, Reubsaet L. Immuno MS-based targeted proteomics: highly specific, sensitive and reproducible hCG determination for clinical diagnostics and doping analysis. Anal. Chem. 84(18), 7926-7932 (2012).
3. Lund H, Snilsberg AH, Halvorsen TG, Hemmersbach P, Reubsaet JL. Sports drug testing using immuno-MS: Clinical study comprising administration of human chorionic gonadotropin to males. Anal. Bioanal. Chem. 405(5), 1569-1576 (2013).
4. Handelsman DJ. The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J. Clin. Endocrinol. Metab. 91(5), 1646-1653 (2006).
5. Cole LA. Human chorionic gonadotropin and associated molecules. Expert Rev. Mol. Diagn. 9, 51-73 (2009).
6. Mitchell H, Seckl MJ. Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG. Mol. Cell. Endocrinol. 260-262, 310-313 (2007). (Pubitemid 44803081)
7. Sturgeon CM, Berger P, Bidart J-M et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin. Chem. 55(8), 1484-1491 (2009).
8. Lund H, Torsetnes SB, Paus E, Nustad K, Reubsaet LO, Halvorsen TG. Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples. J. Proteome Res. 8(11), 5241-5252 (2009).
9. Pettersson K, Siitari H, Hemmilä I et al. Time-resolved fluoroimmunoassay of human choriogonadotropin. Clin. Chem. 29(1), 60-64 (1983). (Pubitemid 13167621)
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476), 307-310 (1986). (Pubitemid 16134762)
11. Alfthan H, Haglund C, Roberts P, Stenman UH. Elevation of free beta-subunit of human choriogonadotropin and core beta-fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res. 52(17), 4628-4633 (1992).
12. Cole LA, Khanlian SA, Muller CY, Giddings A, Kohorn E, Berkowitz R. Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free [beta]-subunit, a reliable marker of placental site trophoblastic tumors. Gynecol. Oncol. 102(2), 160-164 (2006). (Pubitemid 44063586)
13. Lempiainen A, Stenman U-H, Blomqvist C, Hotakainen K. Free {beta}-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. Clin. Chem. 54(11), 1840-1843 (2008).
14. Marcillac I, Cottu P, Theodore C, Terrierlacombe MJ, Bellet D, Droz JP. Free hCG-beta subunit as tumor-marker in urothelial cancer. Lancet 341(8856), 1354-1355 (1993). (Pubitemid 23148140)
15. Marcillac I, Troalen F, Bidart JM et al. Free human chorionic gonadotropin beta-subunit in gonadal and nongonadal neoplasms.Cancer Res. 52(14), 3901-3907 (1992).
16. Cole L. New discoveries on the biology and detection of human chorionic gonadotropin. Reprod. Biol. Endocrin. 7(1), 8 (2009).
17. Stenman U-H, Tiitinen A, Alfthan H, Valmu L. The classification, functions and clinical use of different isoforms of HCG. Hum. Reprod. Update 12(6), 769-784 (2006). (Pubitemid 44605514)
18. Bristow A, Berger P, Bidart J-M et al. Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin. Chem. 51(1), 177-182 (2005). (Pubitemid 40024028)
19. Mccready J, Braunstein GD, Helm D, Wade ME. Modification of the choriogonadotropin beta-subunit radioimmunoassay for determination of urinary choriogonadotropin. Clin. Chem. 24(11), 1958-1961 (1978). (Pubitemid 9049069)
20. Wilcox AJ, Weinberg CR, Wehmann RE, Armstrong EG, Canfield RE, Nisula BC. Measuring early pregnancy loss: Laboratory and field methods. Fertil. Steril. 44(3), 366-374 (1985). (Pubitemid 15232337)
21. Lempiäinen A, Hotakainen K, Alfthan H, Stenman U-H. Loss of human chorionic gonadotropin in urine during storage at -20°C. Clin. Chim. Acta 413(1-2), 232-236 (2012).
22. Robinson N, Sottas P-E, Saugy M. Evaluation of two immunoassays for the measurement of human chorionic gonadotropin in urine for anti-doping purposes. Clin. Lab. 56(5-6), 197-206 (2010).
23. Cole L. Familial HCG syndrome. J. Reproduct. Immunol. 93(1), 52-57 (2012).
24. Berger P, Sturgeon C, Bidart JM et al. The ISOBM TD-7 workshop on hCG and related molecules - towards user-oriented standardization of pregnancy and tumor diagnosis: Assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumor Biol. 23(1), 1-38 (2002). (Pubitemid 34225019)